Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
The calcium antagonist controversy: A posthumous commentary
Franz H. Messerli
*
,
Ehud Grossman
*
Corresponding author for this work
Faculty of Medicine
Ochsner Health System
Research output
:
Contribution to journal
›
Article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The calcium antagonist controversy: A posthumous commentary'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Calcium Antagonists
100%
Short-acting
37%
Patients with Diabetes
25%
Myocardial Infarction
25%
Apoptosis
12%
Drug Class
12%
Parkinsonism
12%
Suicide
12%
Retrospective Survey
12%
Risk Factors
12%
Malignancy
12%
Beneficial Effects
12%
Cognitive Dysfunction
12%
Hypertension
12%
High Mortality Rate
12%
Cardiovascular Disease
12%
Left Ventricular Hypertrophy
12%
Patients with Hypertension
12%
Congestive Heart Failure
12%
Ischemic Heart Disease
12%
Sympathetic Nerve Activity
12%
Dihydropyridine
12%
Coronary Events
12%
Risk of Malignancy
12%
Cardiovascular Drugs
12%
Non-dihydropyridine
12%
Dilated Cardiomyopathy
12%
Immunosuppression
12%
Calcium Disorders
12%
Medicine and Dentistry
Calcium Antagonist
100%
Patient with Diabetes
25%
Myocardial Infarction
25%
Cancer
25%
Prospective Study
12%
Ischemic Heart Disease
12%
Mortality Rate
12%
Cardiovascular Disease
12%
Left Ventricular Hypertrophy
12%
Patient with Hypertension
12%
Congestive Heart Failure
12%
Programmed Cell Death
12%
Retrospective Study
12%
Short Acting Drug
12%
Dilated Cardiomyopathy
12%
Cardiovascular Agent
12%
Cognitive Defect
12%
Parkinsonism
12%
Immunosuppressive Treatment
12%
Disease
12%
Dihydropyridine
12%
Pharmacology, Toxicology and Pharmaceutical Science
Calcium Antagonist
100%
Heart Infarction
25%
Cognitive Defect
12%
Parkinsonism
12%
Mortality Rate
12%
Ischemic Heart Disease
12%
Heart Left Ventricle Hypertrophy
12%
Prospective Study
12%
Congestive Heart Failure
12%
Retrospective Study
12%
Cardiovascular Agent
12%
Congestive Cardiomyopathy
12%
Short Acting Drug
12%
Cardiovascular Disease
12%
Dihydropyridine
12%